Arcus Biosciences paid its 5 named executives $23.9M in total in FY2025 (Dec). CEO Terry Rosen, Ph.D. was paid $9.7M of that.
PayNo stock prices for these years
Pay of each named executive
Terry Rosen, Ph.D.Chief Executive Officer and Director
| FY2025 (Dec) | |||||||
| FY2024 (Dec) | Not disclosed | ||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
5 years
Richard Markus, M.D., Ph.D.Chief Medical Officer
| FY2025 (Dec) |
1 year
Juan Carlos Jaen, Ph.D.President
| FY2025 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
4 years
Jennifer JarrettChief Operating Officer
| FY2025 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
4 years
Robert C. Goeltz, IIChief Financial Officer
| FY2025 (Dec) | |||||||
| FY2023 (Dec) | |||||||
| FY2022 (Dec) | Not disclosed | ||||||
| FY2021 (Dec) | Not disclosed |
4 years
CEO pay against the pay peers
In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.6M. The CEO of Arcus Biosciences was paid $9.7M, 71% above the median.
- 1BridgeBio Pharma
- 2ImmunityBio
- 3Arcus BiosciencesThis company
- 4Arvinas
- 5Denali Therapeutics
- 6Kura Oncology
- 7Regenxbio
- 8Alector, Inc.Not disclosed
- 9Allogene Therapeutics, Inc.Not disclosed
- 10Arrowhead Pharmaceutics, Inc.Not disclosed
- 11Day One Biopharmaceuticals, Inc.Not disclosed
- 12Editas Medicine, Inc.Not disclosed
- 13Intella Therapeutics Inc.Not disclosed
- 14Iovance BiotherapeuticsNot disclosed
- 15Prothena Corporation PlcNot disclosed
- 16SpringWorks Therapeutics, Inc.Not disclosed
- 17Syndax PharmaceuticalsNot disclosed
- 18XencorNot disclosed
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.